OC.qxp[removed]:37 PM

First Page		Document Content
Date: 2011-04-07 07:20:33 Medicine Protease inhibitors Non-nucleoside reverse transcriptase inhibitors Carbamates Cyclopropanes Antiretroviral drug Darunavir Efavirenz Lopinavir/ritonavir Chemistry Organic chemistry HIV/AIDS		OC.qxp[removed]:37 PM Add to Reading List Source URL: www.bhiva.org Download Document from Source Website File Size: 3,41 MB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas DocID: 1gtlL - View Document
	SUPPLEMENT ARTICLE Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs Stefan Mauss1 and Hartwig Klinker2 1 DocID: 1giaR - View Document
	AIDS Research and Therapy BioMed Central Research DocID: 1aNo3 - View Document
	MS&D logo_no qualifier_2 lines DocID: 1a8lZ - View Document
	Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I DocID: 1a178 - View Document